The efficacy of hyperbaric oxygen (HBO) therapy combined with intravenous edaravone (free radical scavenger) administration was prospectively investigated in patients with acute embolic stroke involving the anterior cerebral circulation. Patients with acute embolic stroke in the anterior cerebral circulation admitted within 48 hours of onset from August 2001 to March 2002 with National Institutes of Health Stroke Scale (NIHSS) scores on admission of 5 or more were assigned randomly to HBO and control groups. The HBO group underwent HBO therapy combined with intravenous edaravone administration for 7 days, whereas the control group received only conventional treatment. The primary endpoint was the modified Rankin Scale score at 90 days (favorable outcome, score 0 or 1). The secondary endpoint was the NIHSS score at 7 days. Analysis was carried out by intention to treat. Six of the 19 patients in the HBO group, but only one of the 19 patients in the control group, had favorable outcomes at 90 days (p º 0.05), although NIHSS score at 7 days did not differ significantly between the two groups. HBO therapy combined with intravenous edaravone administration appears to be effective for the treatment of patients with acute embolic stroke in the anterior cerebral circulation.
Introduction
Hyperbaric oxygen (HBO) therapy for acute cerebral ischemia has been evaluated by animal experiments 5, 12, 18, 24) and human clinical observations. 3, 8, 10, 13, 15, 20) The experimental studies suggested considerable potential, 5, 12, 18, 24) but the clinical effectiveness in patients with acute ischemic stroke has been controversial. With the exception of three studies, 3, 15, 20) the major criticism of most clinical investigations has been the lack of controlled prospective analysis. 14) Oxygen free radicals, which may be produced by HBO therapy 6) or by breathing 100% oxygen, 11) are likely to be important in the mechanism of damage caused by cerebral ischemia. 22) Edaravone, a novel free radical scavenger, is reported to be effective in the treatment of patients with acute ischemic stroke. 7) Therefore, HBO therapy combined with intravenous edaravone may improve long-term clinical outcome by protecting the central nervous system against damage from ischemia and free radicals introduced by oxygen therapy.
The present study prospectively investigated the feasibility, safety, and efficacy of HBO therapy combined with intravenous edaravone administration for the treatment of patients with acute embolic stroke in the anterior cerebral circulation.
Materials and Methods
Seventy-five of 201 consecutive patients with ischemic stroke admitted to our institution within 48 hours of onset from August 2001 to March 2002 had acute embolic stroke in the anterior cerebral circulation. Screening of the 75 patients excluded 37 patients for the following reasons: no neuroimaging evidence of complete ischemic stroke and/or fibrinolytic treatment in 13 patients; National Institutes of Health Stroke Scale (NIHSS) score of 4 or less at baseline in 12; medical contraindication for HBO therapy in five; rapid improvement of neurological signs in four; seizure at stroke onset in two; and refusal to participate in one. This study was approved by our institutional ethics committee. Patient or proxy consent was obtained before subject enroll- 
ment.
The diagnosis of embolic stroke was based on at least two of the following criteria: abrupt onset of focal neurological symptoms, middle cerebral artery (MCA) territory infarction involving the cortex on magnetic resonance (MR) imaging or computed tomography (CT), and evidence of single or multiple emboli in other organs. Presence of an embolic source suggesting either cardiogenic embolism or carotid atheroembolism was supportive but not necessary for diagnosis. The site of arterial occlusion was identified on the day of admission by MR angiography, transcranial color flow imaging, or four-vessel angiography.
Nineteen of the 38 patients were randomized to the HBO group and 19 to the control group. Patients in the two groups were well matched with respect to baseline characteristics, except that more patients in the HBO group had occlusion of proximal arteries such as the internal carotid artery or MCA involving lenticulostriate arteries (HBO group 9, control group 3; p ＝ 0.039) ( Table 1) .
Patients in the HBO group underwent 1 hour of HBO per day for 7 days in a chamber (Model 2800J; Sechrist Industries Inc., Anaheim, Calif., U.S.A.) pressured with 100% oxygen to 2.0 atm absolute pressure (ATA). Edaravone (30 mg) was administered intravenously over 60 minutes immediately before and after each HBO therapy session. Both the HBO and control groups received 10000 U of heparin per day for 7 days by continuous intravenous infusion. Treatment in the HBO chamber was supervised by a medical engineer to ensure that compression and decompression rates did not exceed 0.1 ATA/min. Electrocardiography and blood pressure monitoring were continued during each compression/decompression cycle. Intravenous infusion of 400 to 600 ml of 10% glycerol was given if needed in both groups.
NIHSS scores on admission (at baseline) and at 7 days after admission, and the modified Rankin Scale score at 90 days after admission were recorded. The primary endpoint was the modified Rankin Scale at 90 days (favorable outcome, score 0 or 1). The secondary endpoint was the NIHSS score at 7 days. Further endpoints were improvement in NIHSS score at 7 days after admission; survival for 90 days; treatment complications including parenchymal hematoma 17) on cerebral CT; and abnormal findings in laboratory tests at 7 days. Improvement in NIHSS score was compared between and within groups.
Statistical analysis was performed based on intention to treat. Baseline patient characteristics were compared by either Fisher's exact test or the unpaired t test, and median NIHSS scores at 7 days and median improvement in NIHSS scores were compared between groups with Mann-Whitney's U test. Numbers of patients with favorable outcomes at 90 days, survival at 90 days, and treatment complications were compared between groups with Fisher's exact test. Intragroup improvement of NIHSS score 7 days after admission was estimated in each group with Wilcoxon's rank sum test. A value of p º 0.05 was considered statistically significant. SPSS software (StatView, version 5; SAS Institute Inc., Cary, N.C., U.S.A.) was used to perform all statistical analyses. 
Results
All 38 patients were followed up for 90 days. Six patients had favorable outcomes at 90 days in the HBO group, whereas only one patient had a favorable outcome in the control group (Fisher's exact test, p ＝ 0.045) ( Table 2 ). No significant difference between groups was evident in the number of patients surviving at 90 days (Table 2) . Three patients in the HBO group died, two of pneumonia and one of heart failure. One patient died of heart failure in the control group. No significant differences were present between the groups in median NIHSS scores at baseline or at 7 days (Table 2) . On the other hand, median intergroup improvement in NIHSS score was 5 in the HBO group and 1 in the control group (MannWhitney U test, p º 0.01) ( Table 2 ). Intragroup improvement of NIHSS score at 7 days after admission was significantly better in the HBO group (Wilcoxon's rank sum test, p º 0.01) (Fig. 1) .
No life-threatening complications occurred in either group. Minor complications of HBO therapy included transient otalgia in five patients, transient hypertension in three, low back pain in one, and transient tachycardia in one. No complication required modification of treatment except for one patient with ear pain not requiring myringotomy, for whom the pressure in the HBO chamber was increased gradually and maintained at 1.5 ATA. CT at 7 days disclosed parenchymal hematoma in one patient in the HBO group and two patients in the control group (no significant difference). No abnormal findings were disclosed by laboratory tests.
Discussion
In the present study, HBO therapy combined with intravenous edaravone administration improved the 90-day clinical outcome in patients with acute embolic stroke involving the anterior cerebral circulation. The proportion of patients with favorable outcome according to the modified Rankin Scale at 90 days was significantly greater in the HBO group. Although no differences were found in NIHSS score at 7 days between the two groups, intergroup and intragroup improvements in the NIHSS score at 7 days were significantly better in the HBO group. No life-threatening complications occurred in either group. These findings suggest that HBO therapy
combined with intravenous edaravone administration is safe and effective for the treatment of patients with acute embolic stroke involving the anterior cerebral circulation.
HBO therapy has been used for treatment of ischemic stroke with the intent of oxygenating the ischemic penumbra 4) and inducing vasoconstriction to decrease intracranial pressure. 14) However, previous randomized controlled human studies of HBO therapy have demonstrated no benefit, 3, 15, 20) and the American Stroke Association guidelines for the early management of patients with ischemic stroke suggest that the evidence does not support the general use of HBO therapy in patients with acute ischemic stroke. 2) Precisely why our combined treatment achieved a favorable clinical outcome is unclear. The four possibly important factors include case selection (embolic stroke), timing of first HBO therapy, total dose of HBO, and intravenous administration of edaravone.
Embolic stroke may respond more favorably to HBO than other types. In previous studies, patients with various ischemic stroke subtypes were included in the group treated unsuccessfully with HBO, 3, 15, 20) whereas we studied only patients with embolic stroke. As about 40% of occluded arteries recanalize spontaneously within a few days after the embolic stroke onset, 9) HBO may minimize brain damage adjunctively 8, 10) by maintaining the viability of the ischemic penumbra until spontaneous recanalization. Furthermore, since HBO reduced cerebral edema in some experimental studies, 23) HBO also may help to decrease the volume effects of brain edema in patients with embolic stroke.
Timing of the first exposure to HBO is probably important for the optimum effect. In our study, the inclusion criterion required presentation within 48 hours of onset, and the mean elapsed time to initiation of intravenous edaravone administration was 546 minutes. This delay to HBO was shorter than in some previous studies. 3, 15) Twelve of our 19 patients received initial HBO therapy within 6 hours of symptom onset. Treatment of a rat model of 2-hour MCA occlusion with HBO within 6 hours of reperfusion was found to decrease the area of infarction. 5) We believe that early application of HBO while the ischemic penumbra was viable was crucial to our favorable results.
The total amount of HBO treatment may be important. The literature offers little guidance about pressure, duration, intertreatment intervals, and total number of hyperbaric exposures. Our treatment protocol was developed empirically. The efficacy of HBO is reported to depend on the total dose calculated as the product of ATA (P), duration of a single hyperbaric exposure (D), and number of exposures (N). 19) Our total dose was 14 as calculated by 2 ATA (P) × 1 hour (D) × 7 days (N), attaining the optimal proposed dose (more than 13). 19) We believe that the total dose of HBO in our protocol was sufficient to demonstrate any effect in patients with embolic stroke.
Edaravone, a novel free radical scavenger, had a neuroprotective effect in acute ischemic stroke in animal 1, 16) and human 7) studies. Edaravone may be important in scavenging free radicals that might be generated during HBO therapy using 100% oxygen. 6, 25) In addition, recanalization commonly occurs in patients with acute embolic stroke, and free radicals and lipid peroxidation are produced during 21) or after 22) reperfusion following complete ischemia. Oxygen free radicals and lipid peroxidation are believed to cause brain injury following cerebral ischemia. 22) We suggest that edaravone combined with HBO therapy can reduce the brain damage caused by 100% oxygen and/or reperfusion injury in patients with acute embolic stroke. However, a specific scavenger of superoxide, superoxide dismutase, combined with HBO was ineffective in increasing survival rates of gerbils with global brain ischemia. 18) Also, breathing 100% oxygen after 15 minutes of global brain ischemia not followed by reperfusion increased lipid peroxidation and mortality in gerbils. 11) On the other hand, HBO did not increase brain lipid peroxidation if administered to rats after 10 minutes of focal brain ischemia not followed by reperfusion, 24) and HBO increased free radicals but not lipid peroxidation if started within 1 minute of reperfusion following cerebral ischemia in a rabbit model. 12) Therefore, we suspect that HBO probably increases free radicals and lipid peroxidation, particularly in patients with embolic stroke in whom recanalization commonly occurs at various times.
HBO therapy was not associated with severe complications requiring interruption of treatment in our study or in previous reports. 3, 8, 10, 13, 15, 20) HBO was reportedly difficult to administer by schedule and to tolerate, but all of our patients except one underwent HBO on schedule, with no patient refusal to continue. 3) As intravenous edaravone administration also had no major adverse reactions, combined treatment could be performed safely in patients with embolic stroke.
The major limitation in our small pilot trial is that either HBO therapy or intravenous edaravone administration could act independently and lead to a favorable clinical outcome. However, we suspect that the combined action of these treatments resulted in the good outcomes, as intravenous edaravone administration was intended to reduce the possible deleterious effects of HBO. Further study including a larger number of patients will be required for a definitive answer, with assignment to four groups: HBO only, intravenous edaravone administration only, combined treatment, and control. The other limitation in our study is the unique inclusion criteria restricted by our policy on treatment for HBO and Edaravone for Embolic Stroke acute embolic stroke without neuroimaging evidence of completed ischemic stroke in the MCA, which prioritizes localized intraarterial fibrinolysis over neuroprotective treatment such as HBO, and HBO is contraindicated in patients who have received localized intraarterial fibrinolysis until the absence of hemorrhagic transformation can be confirmed by cranial CT 24 hours after the procedure. The therapeutic time window for salvaging penumbral tissue is widely believed to be shorter than the 48 hours of our inclusion criteria. Therefore, further study of HBO therapy combined with intravenous edaravone administration for patients with acute stroke without neuroimaging evidence and/or within 24 hours of onset of embolic stroke is needed, although only two of our 19 patients received initial HBO over 24 hours after symptom onset.
HBO therapy combined with intravenous edaravone administration appears to be feasible, safe, and effective for the treatment of patients with acute embolic stroke involving the anterior cerebral circulation.
